Statistics about Guillain-Barre Syndrome

About statistics: This page presents a variety of statistics about Guillain-Barre Syndrome. The term 'prevalence' of Guillain-Barre Syndrome usually refers to the estimated population of people who are managing Guillain-Barre Syndrome at any given time. The term 'incidence' of Guillain-Barre Syndrome refers to the annual diagnosis rate, or the number of new cases of Guillain-Barre Syndrome diagnosed each year. Hence, these two statistics types can differ: a short-lived disease like flu can have high annual incidence but low prevalence, but a life-long disease like diabetes has a low annual incidence but high prevalence. For more information see about prevalence and incidence statistics.

Prevalence and incidence statistics for Guillain-Barre Syndrome: (see also prevalence and incidence page for Guillain-Barre Syndrome)
  Prevalance of Guillain-Barre Syndrome: about 1 in 100,000 (NWHIC)
  Prevalance Rate: approx 1 in 100,000 or 0.00% or 2,720 people in USA [about data]
  Incidence (annual) of Guillain-Barre Syndrome: about 1 in 100,000 (NWHIC)
  Incidence Rate: approx 1 in 100,000 or 0.00% or 2,720 people in USA [about data]
  Prevalance of Guillain-Barre Syndrome: Guillain Barre Syndrome (GBS) is a rare disorder, afflicting about 1 person in 100,000.¹
  Incidence of Guillain-Barre Syndrome: The syndrome is rare, however, afflicting only about one person in 100,000.²
  Prevelance statistics about Guillain-Barre Syndrome: The following statistics relate to the prevalence of Guillain-Barre Syndrome:

GBS affects men and women equally in the US (NIH, The National Women’s Health Centre, 2004)
GBS affects 1 person per 100,000 population in the US (NIH, The National Women’s Health Centre, 2004)

Society statistics for Guillain-Barre Syndrome
Costs for Guillain-Barre Syndrome: $247 million to $1.8 billion for Campylobacter induced GBS (NIAID)
Costs for Guillain-Barre Syndrome: The medical costs associated with Campylobacter induced GBS has been estimated by the USDA to be between $57 and $425 million per year in the U.S. Total costs, which include days of lost productivity, are estimated to be between $247 million and $1.8 billion per year.¹ '

Footnotes:
1. excerpt from NIAID Guillain Barre Fact Sheet: NIAID
2. excerpt from Guillain-Barre Syndrome: NWHIC

Last revision: May 28, 2003

Medical Tools & Articles:

Next articles:

Medical Articles: